XXXX in the management of severe @entity1569 .

@entity1 @entity137 @entity1569 @entity2905 @entity15627
BACKGROUND: @entity15627 (FAEs) offer an effective alternative to @entity1 with @entity1569 in whom other systemic agents are contraindicated or have failed. OBJECTIVE: We assessed the efficacy and side effect profile of FAEs in a group of @entity1 with @entity1569 . METHODS: A retrospective study was carried out on @entity1 treated with FAEs over 21 months. Information was gathered from @entity1 ' notes. Dosage, response and side effects were recorded. RESULTS: In total, 31 @entity1 were included. The mean age was 46.8 years. All @entity1 had been treated with other modalities and 61.5% had received previous systemic treatment. There was good to excellent response in 58.6% of @entity1 . Subjective side-effects were common (87.1%), and @entity2905 occurred in 61.3%. The drug was not tolerated by one-fifth of @entity1 . CONCLUSION: The relatively low @entity137 and absence of hepatotoxicity makes FAEs a reasonable first-line systemic treatment in selected @entity1 with difficult @entity1569 .
